口服麦芽酚铁治疗CKD患者缺铁性贫血:随机试验与开放标签扩展
这项3期双盲随机安慰剂对照试验(AEGIS-CKD)纳入167例3-4期CKD合并缺铁性贫血患者,口服麦芽酚铁30mg或安慰剂每日两次治疗16周。结果显示麦芽酚铁组血红蛋白较安慰剂显著升高(差值0.5 g/dL,95%CI 0.1-0.9,P=0.01),铁蛋白、转铁蛋白饱和度和血清铁亦改善,且疗效维持至52周,耐受性良好。
要点
- 麦芽酚铁30mg每日两次可显著改善CKD3-4期缺铁性贫血患者的血红蛋白和铁指标。
- 血红蛋白提升幅度较小(较安慰剂差值0.5 g/dL),但铁指标全面改善且可持续至52周。
- 胃肠道不良事件常见,但导致停药的比例较低。
核心结论
- 麦芽酚铁在CKD合并缺铁性贫血患者中16周时显著且持续至52周升高血红蛋白和铁指标,耐受性良好。
研究设计与样本
- 3期双盲随机安慰剂对照试验(AEGIS-CKD)及开放标签扩展,纳入167例3或4期CKD合并缺铁性贫血的成人患者,来自30个美国中心。
- 随机阶段按2:1接受口服麦芽酚铁30mg或安慰剂每日两次治疗16周,随后所有患者接受麦芽酚铁30mg每日两次至最多36周。
主要发现
- 第16周时,麦芽酚铁组血红蛋白较安慰剂组显著升高(最小二乘均值差0.5±0.2 [SE] g/dL;95%CI 0.1-0.9;P=0.01)。
- 铁蛋白、转铁蛋白饱和度和血清铁在麦芽酚铁组升高,而安慰剂组下降(均P<0.05)。
- 继续麦芽酚铁治疗的患者血红蛋白水平维持至第52周,从安慰剂转换为麦芽酚铁的患者血红蛋白也升高。
- 最常见不良事件为胃肠道事件(随机阶段:麦芽酚铁组41% vs 安慰剂组30%;开放标签阶段:56% vs 46%)。
- 双盲治疗期间,麦芽酚铁组7例(6%)和安慰剂组5例(9%)因不良事件退出;开放标签扩展期间11例(9%)退出。
临床怎么用
- 对于CKD 3-4期合并缺铁性贫血且未接受肾脏替代治疗的患者,口服麦芽酚铁可作为铁替代治疗选择之一。
- 治疗期间需监测血红蛋白和铁指标,并关注胃肠道不良反应。
局限性
- 基线铁蛋白水平存在异质性。
- 女性参与者比例较高。
- 开放标签扩展为单臂设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Iron-deficiency anemia is common in patients with chronic kidney disease (CKD) not requiring kidney replacement therapy (KRT). We evaluated effects of oral iron replacement therapy with ferric maltol in these patients. STUDY DESIGN: Phase 3, double-blind, randomized, placebo-controlled trial (AEGIS-CKD) and open-label extension. SETTING & PARTICIPANTS: Adults with stage 3 or 4 CKD and iron-deficiency anemia at 30 US centers. INTERVENTION: Oral ferric maltol at 30mg or placebo twice daily for 16 weeks (2:1 randomization) followed by ferric maltol at 30mg twice daily for up to 36 weeks (all patients). OUTCOME: Change from baseline in hemoglobin (primary end point at week 16), ferritin, transferrin saturation, and serum iron; safety. RESULTS: 167 patients were randomized (ferric maltol, n=111; placebo, n=56). At week 16, hemoglobin had increased significantly with ferric maltol versus placebo (least-squares mean difference: 0.5±0.2 [SE] g/dL; 95% CI, 0.1-0.9; P=0.01). Ferritin, transferrin saturation, and serum iron increased with ferric maltol but declined with placebo (all P<0.05). Hemoglobin levels were sustained up to week 52 in patients continuing ferric maltol and increased in patients switching from placebo to ferric maltol. The most frequent adverse events were gastrointestinal (randomized phase: 41% vs 30% [ferric maltol vs placebo]; open-label phase: 56% vs 46%, respectively). Adverse events led to treatment withdrawal in 7 patients (6%) receiving ferric maltol and 5 patients (9%) receiving placebo during double-blind treatment, and 11 patients (9%) during the open-label extension. LIMITATIONS: Heterogeneity in baseline ferritin levels; high proportion of female participants; single-arm open-label extension. CONCLUSIONS: Ferric maltol was associated with statistically significant (week 16) and sustained (up to week 52) increases in hemoglobin and iron indices in patients with CKD and iron deficiency, and was well tolerated during treatment for up to 52 weeks. FUNDING: Funded by Shield Therapeutics (UK) Ltd. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT02968368.
引用
- Pergola PE, Kopyt NP. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension. Am J Kidney Dis. 2021. PMID: 34029682. doi:10.1053/j.ajkd.2021.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。